Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its participation in upcoming investor conferences. These include the Berenberg U.S. CEO Conference on November 12, 2020, the Stephens Annual Investment Conference on November 19, 2020, and the Piper Sandler 32nd Annual Healthcare Conference with events on November 23 and December 2, 2020. Live webcasts of these events will be accessible on Glaukos' investor website. Glaukos focuses on innovative therapies for glaucoma and corneal disorders, pioneering Micro-Invasive Glaucoma Surgery.
- None.
- None.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:
- Berenberg U.S. CEO Conference on Thursday, November 12, 2020 (one-on-one and group meetings only)
- Stephens Annual Investment Conference on Thursday, November 19, 2020 at 8:00 a.m. PST
- Piper Sandler 32nd Annual Healthcare Conference (a pre-recorded fireside chat presentation will be available for viewing beginning on Monday, November 23, 2020; management will participate in one-on-one and group meetings on Wednesday, December 2, 2020)
A live and archived webcast for these event, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent inject® W device in the United States in October 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
